Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Eight RNAi-Related Patent Applications: Jul 24, 2008

Premium
Title: Method and Medicament for Inhibiting the Expression of a Given Gene
 
Number: 20080171862 & 20080171861
 
Filed: Oct. 31, 2007
 
Lead Inventor: Roland Kreutzer, Alnylam Europe (Alnylam Pharmaceuticals)
 
The patent applications, their abstracts state, claim “an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA.”
 

 
Title: RNAi-Mediated Inhibition of Aquaporin 1 for Treatment of IOP-Related Conditions
 
Number: 20080171719
 
Filed: Nov. 28, 2007
 
Lead Inventor: Jon Chatterton, Alcon
 
The patent application, its abstract states, claims “RNA interference … for inhibition of aquaporin 1 in intraocular pressure-related conditions, including ocular hypertension and glaucoma, such as normal-tension glaucoma and open-angle glaucoma.”
 

 
Title: Nucleic Acid Modulation of Toll-Like Receptor-Mediated Immune Stimulation
 
Number: 20080171716
 
Filed: Aug. 15, 2007
 
Lead Inventor: Ian MacLachlan, Protiva Biotherapeutics (Tekmira Pharmaceuticals)
 
According to the patent application’s abstract, the invention “provides methods of modulating the activation of certain Toll-like receptors such as TLR7/8 using chemically modified nucleic acid molecules … [as well as] methods of using such modified nucleic acid molecules to treat diseases or disorders associated with TLR7/8 activation such as systemic lupus erythematosus.”
 
The abstract adds that the invention “further provides compositions comprising a combination of modified nucleic acid molecules and nucleic acid molecules that silence expression of one or more target sequences. Methods of using such compositions to reduce or abolish target gene expression without inducing cytokine production are also provided.”
 

 
Title: Methods and Compositions Involving miRNA and miRNA Inhibitor Molecules
 
Number: 20080171715
 
Filed: Aug. 10, 2007
 
Lead Inventor: David Brown, Ambion (Asuragen)
 
The invention “concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules,” the patent application’s abstract states. “Moreover, the … invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.”
 

 
Title: Methods and Compositions Involving microRNA
 
Number: 20080171667
 
Filed: Aug. 11, 2007
 
Lead Inventor: David Brown, Ambion (Asuragen)
 
The invention “concerns methods and compositions for isolating, enriching, and/or labeling miRNA molecules and for preparing and using arrays or other detection techniques for miRNA analysis,” the patent application’s abstract states. “Moreover, the … invention concerns methods and compositions for generating miRNA profiles and employing such profiles for therapeutic, diagnostic, and prognostic applications.”
 

 
Title: Expression System
 
Number: 20080171358
 
Filed: June 1, 2005 PCT Filed: June 1, 2005
 
Inventor: Jacques Perrault, San Diego State University
 
The invention “relates generally to methods and compositions for expression of polypeptides or delivery of interfering RNAs in various cell types,” according to the patent application’s abstract.
 

 
Title: Highly Branched Hk Peptides as Effective Carriers of siRNA
 
Number: 20080171025
 
Filed: Nov. 17, 2005 PCT Filed: Nov. 17, 2005
 
Inventor: Archibald Mixson, University of Maryland School of Medicine
 
The invention, the patent application’s abstract states, “is directed to methods of transfecting cells with siRNA by contacting a transfection complex with one or more cells, where the transfection complex includes a transport polymer and siRNA. … The invention is also directed to such transfection complexes and to compositions that include such transfection complexes. The invention is further directed to methods of treating patients using the transfection complexes.”
 

 
Title: Macromolecular Compositions That Cross the Blood-Brain Barrier and Methods of Use Thereof
 
Number: 20080170994
 
Filed: Aug. 20, 2007
 
Lead Inventor: William Pardridge, Armagen Technologies
 
“The invention provides diagnostic and therapeutic macromolecular compositions that cross the blood-brain barrier, in some embodiments in both directions, while allowing their activity to remain substantially intact once across the barrier,” the patent application’s abstract claims. “Also provided are methods for using such compositions in the diagnosis or treatment of CNS disorders such as Alzheimer's disease.”